Background and Aims NAFLD is a key component of metabolic syndrome, ranging from
nonalcoholic fatty liver to NASH, and is now becoming the leading cause of cirrhosis and …

Nonalcoholic steatohepatitis may develop into hepatic cirrhosis. The therapeutic drugs for
NASH are absent. Baicalin (BC) has hepatoprotective effect, while whether BC could …

Being at the important pathological stage and the critical treatment period of non-alcoholic
fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH) which is associated with …

Nonalcoholic fatty liver disease (NAFLD) is a prevalent chronic liver disease around the
world, imposing severe threats on human health. Unfortunately, no clinically approved drugs …

Objectives: Non-alcoholic fatty liver disease (NAFLD) and its progression to non-alcoholic
steatohepatitis (NASH) and hepatocarcinoma is a serious and growing problem. However …

Non-alcoholic steatohepatitis (NASH) is the progressive stage of non-alcoholic fatty liver
disease that may ultimately lead to cirrhosis and liver cancer, and there are few therapeutic …

Objective Nonalcoholic fatty liver disease (NAFLD) is an inflammatory lipotoxic disorder with
a prevalence of over 25% worldwide. However, safe and effective therapeutic agents for the …

Silymarin, which derived from the milk thistle plant (silybum marianum), has been used for
centuries as a natural remedy for diseases of the liver and biliary tract. Considering the …

Non-alcoholic fatty liver disease (NAFLD) is a common chronic liver disease with high
prevalence in the developed countries. NAFLD has been considered as one of the leading …

With changing lifestyles, non-alcoholic fatty liver disease (NAFLD) has become the most
prevalent liver disease worldwide. A substantial increase in the incidence, mortality, and …